Transition Therapeutics Included in the NASDAQ Global Market

    TORONTO, Jan. 7 /CNW/ - Transition Therapeutics Inc. ("Transition" or the
"Company") (NASDAQ:   TTHI; TSX: TTH), today announced that its common shares
have been approved for listing and will begin trading on the NASDAQ Global
Market on Monday January 7, 2008. Prior to this change, the Company's common
shares had been listed on the NASDAQ Capital Market. Transition's common
shares will continue to trade on the Toronto Stock Exchange in addition to the
NASDAQ Global Market.

    About NASDAQ
    NASDAQ is the largest U.S. electronic stock market. With approximately
3,100 companies, it lists more companies and, on average, trades more shares
per day than any other U.S. market. It is home to companies that are leaders
across all areas of business including technology, retail, communications,
financial services, transportation, media and biotechnology. NASDAQ is the
primary market for trading NASDAQ-listed stocks. For more information about
NASDAQ, visit or the NASDAQ Newsroom at

    About Transition
    Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the
treatment of diabetes. Transition has an emerging pipeline of preclinical drug
candidates acquired externally or developed internally using its proprietary
drug discovery engine. Transition's shares are listed on the NASDAQ under the
symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit

    Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC, SEC or otherwise. Except for historical information, this press
release may contain forward-looking statements, relating to expectations,
plans or prospects for Transition, including conducting clinical trials. These
statements are based upon the current expectations and beliefs of Transition's
management and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include factors
beyond Transition's control and the risk factors and other cautionary
statements discussed in Transition's quarterly and annual filings with the
Canadian commissions.

    %SEDAR: 00015806E

For further information:

For further information: on Transition, visit or contact: Dr. Tony Cruz, Chief Executive
Officer, Transition Therapeutics Inc., Phone: (416) 260-7770, x.223,; Elie Farah, Chief Financial Officer,
Transition Therapeutics Inc., Phone: (416) 260-7770, x.203,

Organization Profile

Transition Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890